AVALO THERAPEUTICS, INC. Cash and Restricted Cash
AVALO THERAPEUTICS, INC. (AVTX) had Cash and Restricted Cash of $85.61 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $85.61M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $25.32M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $16.11M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $27.26M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $85.61M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $25.32M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $16.11M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $27.26M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $42.52M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $125.24M 10-Q · filed 2026-05-13 | |
| 2024-12-31 | $134.70M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $82.03M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $93.56M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $110.31M 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $7.55M 10-K · filed 2026-03-23 | |
| 2023-09-30 | $10.31M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $6.45M 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $16.88M 10-Q/A · filed 2024-07-11 | |
| 2022-12-31 | $13.32M 10-K · filed 2025-03-20 | |
| 2022-09-30 | $17.18M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $11.49M 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $38.80M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $54.86M 10-K · filed 2024-03-29 | |
| 2021-09-30 | $71.90M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $40.63M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $38.59M 10-Q · filed 2022-05-05 | |
| 2020-12-31 | $19.11M 10-K · filed 2023-03-29 | $19.11M 10-K · filed 2021-03-08 |
| 2020-09-30 | $33.67M 10-Q · filed 2021-11-09 | $33.67M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $45.60M 10-Q · filed 2021-08-02 | $45.60M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $5.84M 10-Q · filed 2021-05-13 | $5.84M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $3.73M 10-K · filed 2022-03-02 | $3.73M 10-K · filed 2020-03-11 |
| 2019-09-30 | $5.45M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $9.57M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $16.28M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $10.75M 10-K · filed 2021-03-08 | |
| 2018-09-30 | $7.06M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $2.36M 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $2.67M 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $2.61M 10-K · filed 2020-03-11 | |
| 2017-09-30 | $24.05M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $5.54M 10-Q · filed 2018-08-09 | |
| 2017-03-31 | $3.08M 10-Q · filed 2018-05-11 | |
| 2016-12-31 | $5.20M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |